Profundamente agradecido con todo el equipo de Nefrología del Hospital Clinic, que tras 8 meses me llevo un sinfín de enseñanzas y experiencias en este camino de las Enfermedades Glomerulares y ahora con el gran reto de llevar a cabo el PhD. Moltes gràcies.

Miércoles 23 Julio 👇.

Clinical presentations and outcomes in ANCA vasculitis-GN severe:. 166 patients AAV-GN and eGFR < 15 mL/min/1.73m2. ▫️Start of dialysis in the first 4 weeks.(SCr, alveolar hemorrhage, and PR3-ANCA).▫️Number and Crescentic category.▫️Vasculitis severity.▫️ESKD at 12 months

Día del Fellowship de @GlomConILA !.Excelente participación de nuestros fellows y gran apoyo del faculty @jmoraguti con interesantes casos sobre Glomerulopatía C3

C3 glomerulopathy. ▫️It presents with hematuria, varying degrees of proteinuria and renal failure. ▫️Recurrence:60–90%. ▫️>50%:ESKD within 10 yrs of diagnosis. ▫️Eculizumab (limited success). ▫️RTX and plasma exchange are alternative. ▫️Iptacopan and Pegcetocoplan most promising

Non-invasive Diagnosis of Antinephrin–Associated Podocytopathy. ▫️3 cases. ▫️Detected by immunoprecipitation/ELISA. ▫️Their high specificity for podocytopathies in combination with a strong correlation with disease activity hold the potential for a non-invasive diagnosis

Malignancies and glomerulonephritis:. ▫️Occult malignancies generally manifest within 1 year of initial GN diagnosis. ▫️THSD7A and NELL-1 antibodies are detectable in ∼20%–30% of cases of malignancy-related MN. ▫️Paraneoplastic GNs can be associated with all glomerular lesions

Albuminuria predicts kidney events in IgAN:. MAKE: kidney replacement therapy and ↓>30% in eGFR. 1269 patients .Median follow-up: 5.5 years. uACR gr/gr (HR 95%CI):.▫️0.3–0.5: 1.56 (1.14–2.14).▫️0.5–1.0: 2.04 (1.58-2.64).▫️1.0–1.5: 2.82 (2.1-3.78).▫️≥2.0: 4.53 (3.36–6.11)

Obinutuzumab for remission induction in patients with MPO-AAV:. ▫️Obinutuzumab may be a viable alternative to RTX. ▫️Particularly those presenting with detectable CD19/20+ cells in the affected organ despite successful depletion of these target cells in the periphery

RT @ISNeducation: 23/n #ECNeph @myadla @ISNkidneycare @Dilushiwijay @krithicism .2-step classification of MN based on antigens https://t.co….

Clinical Phenotypes and Renal Outcomes in PLA2R-positive MN:. ▫️Predictors of remission reduction:.-Anti-PLA2R: >100 U/ml; HR 0.56, (0.36-0.88), P=0.01.-Proteinuria: >8 g/24 h; HR 0.43 (0.26-0.73) P=0.002. ▫️High HDL levels were protective: HR 1.01 (1.00-1.02), P=0.048

Cyclophosphamide and Rituximab to Minimize Glucocorticoid Use in ANCA Vasculitis. ▫️112 patients: CYC + RTX . ▫️96%: remission.▫️Median time: 77 days. ▫️5% relapse over 2.9 years follow-up. ▫️Glucocorticoids > 12 weeks vs ≤ 12 weeks more serious infections: 21% vs 7%, p =0.06

Long-term Outcome in Membranous Nephropathy Treated With Rituximab. ▫️ 🗓️ 2000 - 2022.▫️159 patients: 88.1% CR or PR . ▫️Median time (months).-CR 22.6.-PR 6.8. ▫️Factors associated with failure to respond:.-Previous IS .-IFTA ≥ 25%. ▫️Failure to respond: 11.9%.▫️ESKD: 4.4%

I invite you to read this interesting review on Calcimimetics and their participation in vascular calcification. A collaboration with great professionals from the Hospital Clinic and the University of Milan. 🔗

Finerenone in Obesity-Related Glomerulopathy. ▫️Finerenone 10-20 mg: 30 patients .▫️Control: 39 patients.▫️Follow-up: 12 months. ▫️Reduction in 24-hour proteinuria: .-35.03% vs. -11.20%, p= 0.01. ▫️Without a significant increase in adverse events. 🔗

VISIONARY Trial for IgAN. Sibeprenlimab: anti APRIL. ▫️APRIL: promotes the maturation of B lymphocytes, helping plasmoblasts become plasma cells. ▫️51.2% reduction in proteinuria at 40 wk. ▫️The benefit was seen as early as 4 wk after initiating treatment.

Este jueves 22 de Mayo 20 hrs 👇.

Están invitados este miércoles 14 de Mayo 👇.

🔗

IgAN carries elevated risk for kidney outcomes starting at proteinuria levels ≥0.5 g/g in contrast to earlier perceptions that levels below 1 g/g. Composite outcome of ≥50% eGFR decline, kidney failure or mortality. UPCR .▫️<0.5 g/g vs 0.5 – <1 g/g: HR 2.4 (1.1-5.1)

RT @IMINmx: 🚨 ¡ATENTA INVITACIÓN! 🚨. Se parte de nuestro cuarto Expert Talk 2025 ✨. 📆 Jueves 22 de mayo | 20:00 hrs.💻 Acceso Gratuito | Mod….